Platelet-derived growth factor receptor-β expression in human peritoneum

Nephron - Clinical Practice

Volumn 128, Issue 1-2, 2014, Pages 178-184

  Seeger, Harald ^a,b   Braun, Niko ^c   Latus, Joerg ^c   Alscher, M Dominik ^c   Fritz, Peter ^d   Edenhofer, Ilka ^a,b   Biegger, Dagmar ^e   Lindenmeier, Maja ^a,b   Wüthrich, Rudolf P ^a   Segerer, Stephan ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Division of General Internal Medicine and Nephrology Department of Internal Medicine Robert Bosch Hospital   (Switzerland)

^d Institute of Digital Medicine   (Switzerland)

^e DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Encapsulating peritoneal sclerosis; Lymphatic vessels; Platelet derived growth factor receptor ; Podoplanin

Indexed keywords

PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PODOPLANIN; SMOOTH MUSCLE ACTIN;

ADULT; ARTERY WALL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTERSTITIUM; LYMPH VESSEL; MALE; MESOTHELIUM CELL; MIDDLE AGED; PERITONEAL BIOPSY; PERITONEAL FIBROSIS; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; UREMIA; BIOSYNTHESIS; METABOLISM;

FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL FIBROSIS; PERITONEUM; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RETROSPECTIVE STUDIES;

EID: 84927582263     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000368241     Document Type: Article

References (28)

1. Pletinck A, Vanholder R, Veys N, Van Biesen W: Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions. Nat Rev Nephrol 2012; 8:542-550.
2. Devuyst O, Margetts PJ, Topley N: The patho-physiology of the peritoneal membrane. J Am Soc Nephrol 2010; 21:1077-1085.
3. Braun N, Alscher DM, Fritz P, Edenhofer I, Kimmel M, Gaspert A, Reimold F, Bode-Lesniewska B, Ziegler U, Biegger D, Wuthrich RP, Segerer S: Podoplanin-positive cells are a hallmark of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2011; 26:1033-1041.
4. Braun N, Alscher MD, Fritz P, Latus J, Eden-hofer I, Reimold F, Alper SL, Kimmel M, Biegger D, Lindenmeyer M, Cohen CD, Wuthrich RP, Segerer S: The spectrum of podoplanin expression in encapsulating peritoneal sclerosis. PLoS One 2012; 7:e53382.
5. Donovan J, Abraham D, Norman J: Platelet-derived growth factor signaling in mesenchy-mal cells. Front Biosci 2013; 18:106-119.
6. Demoulin JB, Essaghir A: PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev 2014; 25:273-283.
7. Murakami M: Signaling required for blood vessel maintenance: molecular basis and pathological manifestations. Int J Vasc Med 2012; 2012:293641.
8. Chen YT, Chang FC, Wu CF, Chou YH, Hsu HL, Chiang WC, Shen J, Chen YM, Wu KD, Tsai TJ, Duffield JS, Lin SL: Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 2011; 80:1170-1181.
9. Greenhalgh SN, Conroy KP, Henderson NC: Healing scars: targeting pericytes to treat fi-brosis. QJM 2014, Epub ahead of print.
10. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176:85-97.
11. Khairoun M, van der Pol P, de Vries DK, Lie-vers E, Schlagwein N, de Boer HC, Bajema IM, Rotmans JI, van Zonneveld AJ, Rabelink TJ, van Kooten C, Reinders ME: Renal ischemia-reperfusion induces a dysbalance of angiopoi-etins, accompanied by proliferation of peri-cytes and fibrosis. Am J Physiol Renal Physiol 2013; 305:F901-F910.
12. Edwards IJ, Singh M, Morris S, Osborne L, Le Ruez T, Fuad M, Deuchars SA, Deuchars J: A simple method to fluorescently label pericytes in the CNS and skeletal muscle. Microvasc Res 2013; 89:164-168.
13. Armulik A, Genove G, Betsholtz C: Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21:193-215.
14. Hamdan R, Zhou Z, Kleinerman ES: SDF-1al-pha induces PDGF-b expression and the differentiation of bone marrow cells into peri-cytes. Mol Cancer Res 2011; 9:1462-1470.
15. Nakamoto H: Encapsulating peritoneal sclerosis-a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25(suppl 4):S30-S38.
16. Vlijm A, Stoker J, Bipat S, Spijkerboer AM, Phoa SS, Maes R, Struijk DG, Krediet RT: Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2009; 29: 517-522.
17. Honda K, Nitta K, Horita S, Tsukada M, Ita-bashi M, Nihei H, Akiba T, Oda H: Histolog-ic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003; 19:169-175.
18. Ponce AM, Price RJ: Angiogenic stimulus determines the positioning of pericytes within capillary sprouts in vivo. Microvasc Res 2003; 65:45-48.
19. Duffield JS, Lupher M, Thannickal VJ, Wynn TA: Host responses in tissue repair and fibro-sis. Annu Rev Pathol 2013; 8:241-276.
20. Fragiadaki M, Mason RM: Epithelial-mesen-chymal transition in renal fibrosis-evidence for and against. Int J Exp Pathol 2011; 92:143-150.
21. Chen YT, Chang YT, Pan SY, Chou YH, Chang FC, Yeh PY, Liu YH, Chiang WC, Chen YM, Wu KD, Tsai TJ, Duffield JS, Lin SL: Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibro-blasts during peritoneal injury. J Am Soc Nephrol 2014, Epub ahead of print.
22. Beavis MJ, Williams JD, Hoppe J, Topley N: Human peritoneal fibroblast proliferation in 3-dimensional culture: modulation by cyto-kines, growth factors and peritoneal dialysis effluent. Kidney Int 1997; 51:205-215.
23. Patel P, West-Mays J, Kolb M, Rodrigues JC, Hoff CM, Margetts PJ: Platelet derived growth factor b and epithelial mesenchymal transition of peritoneal mesothelial cells. Matrix Biol 2010; 29:97-106.
24. Cina D, Patel P, Bethune JC, Thoma J, Rodri-guez-Lecompte JC, Hoff CM, Liu L, Margetts PJ: Peritoneal morphological and functional changes associated with platelet-derived growth factor b. Nephrol Dial Transplant 2009; 24:448-457.
25. Gordon J, Spiera R: Imatinib and the treatment of fibrosis: recent trials and tribulations. Curr Rheumatol Rep 2011; 13:51-58.
26. Elmholdt TR, Buus NH, Ramsing M, Olesen AB: Antifibrotic effect after low-dose ima-tinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. J Eur Acad Dermatol Venereol 2013; 27:779-784.
27. Velioglu A, Tugtepe H, Asicioglu E, Yilmaz N, Filinte D, Arikan H, Koc M, Tuglular S, Kaya H, Ozener C: Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model. Ren Fail 2013; 35: 531-537.
28. Masunaga Y, Muto S, Asakura S, Akimoto T, Homma S, Kusano E, Asano Y: Ascites from patients with encapsulating peritoneal sclerosis augments NIH/3T3 fibroblast proliferation. Ther Apher Dial 2003; 7:486-493.